[
    [
        {
            "time": "2018-03-15",
            "original_text": "Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study",
            "features": {
                "keywords": [
                    "RET Inhibitor",
                    "Shrinks",
                    "Tumors",
                    "Lung Cancer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Novartis Announces Positive Long-Term Data on Migraine Drug",
            "features": {
                "keywords": [
                    "Novartis",
                    "Positive",
                    "Long-Term",
                    "Migraine",
                    "Drug"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novartis Announces Positive Long-Term Data on Migraine Drug",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "[video]Eli Lilly's Must-Hold Level on Drug-Data Pullback",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Must-Hold",
                    "Drug-Data",
                    "Pullback"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[video]Eli Lilly's Must-Hold Level on Drug-Data Pullback",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Eli Lilly Stock Shrugs Off Upbeat Drug Data",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock",
                    "Upbeat",
                    "Drug Data"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Shrugs Off Upbeat Drug Data",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Lung Cancer",
                    "Treatment",
                    "Strong Results",
                    "Trial"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-25",
            "original_text": "Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",
            "features": {
                "keywords": [
                    "Lilly",
                    "Selpercatinib",
                    "LOXO-292",
                    "Objective Response Rate",
                    "Lung Cancer"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-09-10",
            "original_text": "Lilly's targeted RET drug shrinks tumors in lung cancer trial",
            "features": {
                "keywords": [
                    "Lilly",
                    "RET drug",
                    "shrinks",
                    "tumors",
                    "lung cancer"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's targeted RET drug shrinks tumors in lung cancer trial",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]